RxDoctor Payments Data

Muhammad Khalid, MD

Interventional Cardiology · New Orleans, LANPI 1679536338

Payments from drug & device makers

$3,307in general payments, 2019–2025

Across 165 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$802
  • Medtronic$718
  • Abbott$645
  • Amgen$236
  • EMD Serono, Inc.$219
  • E.r. Squibb & Sons, L.L.C.$126
  • plus $563 from 20 others

What the payments were for

  • Travel & lodging$48415%
  • Food & beverage$2,82385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,307 in reported general payments places this provider in the 15th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$56,818
Medicare patients
107
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$263,280
EntrestoSacubitril/Valsartan80$119,168
Repatha SureclickEvolocumab145$111,937
XareltoRivaroxaban32$35,107
Praluent PenAlirocumab26$13,485
VascepaIcosapent Ethyl20$12,675
BrilintaTicagrelor11$12,049
Repatha SyringeEvolocumab12$6,253
Clonidine24$4,679
Bisoprolol Fumarate155$3,514
Metoprolol Succinate297$2,281
Losartan Potassium254$2,173
Atorvastatin Calcium274$2,030
Carvedilol308$1,995
Potassium Chloride157$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$263,280215 claims
NovartisEntresto$802$119,16880 claims
AstraZenecaBrilinta$18$12,04911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →